BioPharmSignal logoBioPharmSignal

Biotech News

Xenon Announces Azetukalner NDA Submission to FDA for Focal Seizures and Provides Update on Psychiatry Clinical Program

Xenon (XENE)XenonFDA / regulatory

New Drug Application for azetukalner in focal seizures submitted to U.S. Food and Drug Administration; X-TOLE3 and X-ACKT continue to enroll focal seizure and PGTCS patients, respectively Enrollment in X-NOVA2 study in MDD completed with approximately 360 total patients; topline data readout

Related news

CLNNClene Inc.2026-10-19 12:00 EST

Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALS

TEVATeva Pharmaceutical Industries2026-10-09 11:00 EST

Teva Announces U.S. Food and Drug Administration (FDA) Approval of WELTRUZA™ (Olanzapine) For Extended-Release Injectable Suspension, as the First and Only Once-Monthly Subcutaneous Injectable Olanzapine for Adults with Schizophrenia

XERSXeris Pharmaceuticals2026-09-09 12:30 EST

Xeris Hosts Webinar Detailing Its Comprehensive Development Program for XP-8121, an Investigational, Once-Weekly Subcutaneous Levothyroxine for Hypothyroidism

ECORelectroCore2026-10-28 12:00 EST

electroCore, Inc. Submits 510(k) Premarket Notification to FDA Seeking Clearance of Quell® for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy (CIPN)

DNLIDenali Therapeutics2026-10-30 13:30 EST

Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product

CGTXCognition Therapeutics2026-10-22 10:00 EST

Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies

XENEXenon2026-11-03 21:01 EST

Xenon to Present at Upcoming Investor Conferences

XENEXenon2026-11-02 21:02 EST

Xenon to Report Q3 2026 Financial Results on November 9, 2026

SUPNSupernus2026-10-21 23:45 EST

Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl)

ANLAdlai Nortye Ltd.2026-09-08 11:00 EST

Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC

View all latest news

Xenon

Ion-Channel Therapeutics Xenon Pharmaceuticals develops medicines that modulate neuronal ion channels. Its pipeline addresses epilepsy, depression and pain through mechanisms intended to control abnormal electrical signaling. Azetukalner Azetukalner is a selective Kv7 potassium-channel opener intended to reduce excessive neuronal firing....

Recent company news

XENEXenon2026-11-03 21:01 EST

Xenon to Present at Upcoming Investor Conferences

XENEXenon2026-11-02 21:02 EST

Xenon to Report Q3 2026 Financial Results on November 9, 2026

XENEXenon2026-10-30 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

XENEXenon2026-10-29 12:30 EST

Xenon Announces Positive Phase 1 and New Preclinical Data at IASP 2026 Supporting Advancement of XEN1701 and XEN1120 to Phase 2 Proof-of-Concept Studies in Acute Pain

XENEXenon2026-10-02 20:01 EST

Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
37.68 USD
Market cap
5.06B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States